Pyxis Oncology reports positive updated MICVO Phase 1 monotherapy data
Pyxis Oncology said its MICVO Phase 1 monotherapy study showed 36% cORR and 94% DCR, with rapid and deep responses and activity across HPV status and prior-treatment subgroups.
MICVO showed rapid and deep responses, with a 36% confirmed objective response rate (cORR) and a 94% disease control rate (DCR). Clinical activity was seen across HPV status and prior-treatment subgroups. Substantial survival outcomes included median progression-free survival (mPFS) of 6.2 months.